Researchers from Kanazawa University developed a new test for dementia and mild cognitive impairment. The computerized assessment battery for cognition (C-ABC) was able to accurately discriminate mild cognitive impairment from normal cognition, and also distinguish dementia from mild cognitive impairment and normal cognition, and took only 5 minutes to complete. This test could increase the early detection of dementia, thus improving treatment options and outcomes for this patient group.
Researchers have developed a method based on artificial intelligence that rapidly identifies currently available medications that may treat Alzheimer's disease. The method also reveals potential new treatment targets for the disease.
Computational biologists dig into the origins of the single unique protein in the SARS-CoV-2 lineage; pair of new Berkeley Lab reports explores direct and indirect costs of power interruptions to enable better decision making.
MIT finds the APOE4 gene, one of the most significant genetic risk factors for developing Alzheimer's disease, has widespread effects on brain cells' ability to metabolize lipids and respond to stress. Experiments also suggest choline, a widely available supplement, might reverse many of these effects.
Neurodegenerative disorders such as Parkinson's and Alzheimer's disease are in the firing line after researchers identified an attractive therapeutic drug target.
Researchers at UC San Diego School of Medicine and elsewhere have identified a new drug that could prevent AD by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques.
Researchers at the University of California San Diego School of Medicine and Massachusetts General Hospital have identified a new drug that could prevent Alzheimer's disease by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques in the brain. The study, which will be published March 2 in the Journal of Experimental Medicine (JEM), demonstrates that the drug is safe and effective in rodents and monkeys, paving the way for future clinical trials in humans.
Research from the University of Kent has led to the development of the MeshCODE theory, a revolutionary new theory for understanding brain and memory function. This discovery may be the beginning of a new understanding of brain function and in treating brain diseases such as Alzheimer's.
Too much activity in the hippocampus may cause navigation impairments seen in aging adults, according to new research published in JNeurosci.
Promising new research shows aerobic exercise may help slow memory loss for older adults living with Alzheimer's dementia.